An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Summary

Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.

Timeline

Start

2003-11

Primary completion

—

Completion

2007-04

Outcome

Outcome not reported

Stopped: “program discontinued based on GIPF-007 results”

Drugs

Indications